Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study.
Frontiers in Psychiatry 2022 Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin et al. 41 citations
Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects. How patients perceive esketamine treatment, and which conditions facilitate optimal outcomes, remains poorly understood. Understanding patient perspectives on these phenomena is important to identify unmet needs, which can...
DOI: 10.3389/fpsyt.2022.948115 (opens in new tab)
Full text (opens in new tab)
Phenomenology
Patient experience
Set and setting
Treatment-resistant depression trd
+6